Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
Aged
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Female
Fluorodeoxyglucose F18
/ therapeutic use
Humans
Lung Neoplasms
/ diagnostic imaging
Lymph Nodes
/ pathology
Lymphatic Metastasis
Male
Mediastinum
Middle Aged
Neoplasm Staging
Pneumonectomy
Positron Emission Tomography Computed Tomography
Predictive Value of Tests
Preoperative Care
Prognosis
ROC Curve
Retrospective Studies
Lymph node metastasis
Mediastinal staging
N2
Non-small cell lung cancer
Thoracic surgery
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
10
10
2020
revised:
12
12
2020
accepted:
16
12
2020
pubmed:
25
1
2021
medline:
22
12
2021
entrez:
24
1
2021
Statut:
ppublish
Résumé
Despite the recent development of radiologic mediastinal staging modality, unexpected mediastinal lymph node metastasis still occurs. Preoperative accurate nodal staging is important to determine the optimal treatment. Therefore, this study aimed to identify predictors of unexpected N2 disease in non-small-cell lung cancer (NSCLC). Data from a multicenter database of 2802 patients with clinical T1-2N0-1M0 NSCLC who underwent anatomical segmentectomy or lobectomy were retrospectively analyzed. Unexpected N2 disease was defined as pathologic N2 disease with clinical N0 or N1. The predictive criteria of unexpected N2 disease were established on the basis of the multivariable analysis results of a derivation cohort of 2019 patients, and the criteria were further tested in a validation cohort of 783 patients. In multivariable analyses, maximum standardized uptake value (SUV The predictive criteria of unexpected N2 disease (tumors with SUV
Sections du résumé
BACKGROUND
Despite the recent development of radiologic mediastinal staging modality, unexpected mediastinal lymph node metastasis still occurs. Preoperative accurate nodal staging is important to determine the optimal treatment. Therefore, this study aimed to identify predictors of unexpected N2 disease in non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
Data from a multicenter database of 2802 patients with clinical T1-2N0-1M0 NSCLC who underwent anatomical segmentectomy or lobectomy were retrospectively analyzed. Unexpected N2 disease was defined as pathologic N2 disease with clinical N0 or N1. The predictive criteria of unexpected N2 disease were established on the basis of the multivariable analysis results of a derivation cohort of 2019 patients, and the criteria were further tested in a validation cohort of 783 patients.
RESULTS
In multivariable analyses, maximum standardized uptake value (SUV
CONCLUSION
The predictive criteria of unexpected N2 disease (tumors with SUV
Identifiants
pubmed: 33485802
pii: S1525-7304(20)30364-8
doi: 10.1016/j.cllc.2020.12.010
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-126.e3Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.